Thromb Haemost 1998; 79(02): 447-449
DOI: 10.1055/s-0037-1615012
Scientific and Standardization Committee Communication
Schattauer GmbH

Oxidative Stress in Primary Antiphospholipid Syndr ome

P. R. J. Ames
1   Department of Haematology, St. Thomas’ Hospital, Institute of Nephrology, University College Medical School
,
J. Nourooz-Zadeh
1   Department of Haematology, St. Thomas’ Hospital, Institute of Nephrology, University College Medical School
,
C. Tommasino
2   Coagulation Unit, Cardarelli Hospital, Naples, Italy
,
J. Alves
3   Autoimmune Disease Unit, Curry Cabral Hospital, Lisbon, Portugal
,
V. Brancaccio
2   Coagulation Unit, Cardarelli Hospital, Naples, Italy
,
E. E. Anggard
4   William Harvey Research Institute, St. Bartholomew’s Hospital Medical College, London, UK
› Author Affiliations
Further Information

Publication History

Received 07 August 1997

Accepted after revision 17 September 1997

Publication Date:
08 December 2017 (online)

 

 
  • References

  • 1 Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-4.
  • 2 Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, Witzum JL. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996; 98: 815-25.
  • 3 Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Cross-reaction between antibodies to oxidized LDL and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-5.
  • 4 Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
  • 5 Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE. Analysis of F2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 1995 19 (667) 199-208.
  • 6 Morrow JD, Roberts LJ. 2nd The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996; 51: 1-9.
  • 7 Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, Freeman BA. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 1994; 269: 26066-75.
  • 8 Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL. Activation of cultured vascular endothelial cells by anti-phospholipid antibodies. J Clin Invest 1995; 96: 2211-9.
  • 9 Ames PRJ, Pyke S, Iannaccone L, Brancaccio V. Antiphospholipid antibodies, haemostatic variables and thrombosis. A survey on 144 patients. Thromb Haemost 1995; 73: 768-73.
  • 10 Gopaul NK, Nourooz-Zadeh J, Mallet AI, Anggard EE. Formation of F2-isoprostanes during aortic endothelial cell-mediated oxidation of low density lipoprotein. FEBS Lett 1994; 348: 297-300.
  • 11 Galle J, Mulsch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoproteins on formation and activation of endothelial derived relaxing factors. Atherioscler Thromb 1991; 11: 198-203.
  • 12 Halliwell B. Oxidation of low-density lipoproteins: questions of initiation, propagation, and the effect of antioxidants. Am J Clin Nutr 1995; 61: 670S-7S.
  • 13 Anggard E. Nitric oxide: mediator, murderer and medicine. Lancet 1994; 343: 1199-206.
  • 14 Ames PRJ. Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying “membrane stress syndrome” hypothesis. Lupus 1994; 5: 371-7.